Lazard Asset Management LLC Aerie Pharmaceuticals Inc Transaction History

Lazard Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $4,006 - $9,579	-629 Reduced 7.99%	7,248 $109,000
Q2 2022 Aug 09, 2022	BUY	$4.95 - $9.16 $38,991 - $72,153	7,877 New	7,877 $59,000
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $17,190 - $29,870	-3,048 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$7.02 - $13.33 $21,396 - $40,629	3,048 New	3,048 $21,000
Q2 2021 Aug 12, 2021	SELL	$15.16 - $18.97 $51,695 - $64,687	-3,410 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$13.12 - $20.9 $102,480 - $163,249	-7,811 Reduced 69.61%	3,410 $60,000
Q4 2020 Feb 11, 2021	BUY	$9.12 - $14.49 $102,335 - $162,592	11,221 New	11,221 $151,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.